- In September 2025, Lupin's subsidiary formed a partnership with Celnova Pharma to distribute NaMuscla, a medication for non-dystrophic myotonic disorders, in Argentina and Colombia. This collaboration seeks to offer innovative treatment solutions for patients suffering from these rare neuromuscular conditions. The agreement involves the distribution of a drug specifically indicated for treating non-dystrophic myotonic disorders. The pact was established between Lupin Atlantis Holdings SA and Celnova
